Abeona SVP sells shares to cover tax on vesting

Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O’Malley reported small stock sales primarily to cover taxes on vested awards.

Rhea-AI Filing Summary

Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O’Malley reported small stock sales primarily to cover taxes on vested awards. He sold 4,826 shares of common stock at a weighted average price of $5.4295 on June 8, 2026 and 6,305 shares at $5.3042 on June 9, 2026, totaling 11,131 shares. A footnote states the sales were made to cover tax obligations from vesting of restricted stock awards. After these transactions, he directly owned 440,003 shares of Abeona common stock.

Insider Trade Summary

Net Seller: 11,131 shares

Net Sell 2 txns

Insider O'Malley Brendan M.

Role SVP, Chief Legal Officer

Sold 11,131 shs ($60K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,305	$5.3042	$33K
Sale	Common Stock	4,826	$5.4295	$26K

Holdings After Transaction: Common Stock — 440,003 shares (Direct)

Footnotes (3)

1. F1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold June 8, 2026: 4,826 shares Price June 8, 2026: $5.4295 per share Shares sold June 9, 2026: 6,305 shares +3 more

6 metrics

Shares sold June 8, 2026 4,826 shares Common stock open-market sale at weighted average price

Price June 8, 2026 $5.4295 per share Weighted average sale price, range $5.345–$5.54

Shares sold June 9, 2026 6,305 shares Common stock open-market sale at weighted average price

Price June 9, 2026 $5.3042 per share Weighted average sale price, range $5.24–$5.47

Total shares sold 11,131 shares Sum of June 8 and June 9, 2026 sales

Shares owned after sales 440,003 shares Direct common stock holdings post-transaction

Key Terms

restricted stock awards, weighted average price, open-market sale, Common Stock

4 terms

restricted stock awards financial

"tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abeona Therapeutics (ABEO) report for Brendan O’Malley?

Abeona Therapeutics reported that SVP and Chief Legal Officer Brendan M. O’Malley sold 11,131 shares of common stock over two days. These transactions were disclosed as open-market sales and were tied to tax obligations from recently vested restricted stock awards.

Why did Brendan O’Malley sell Abeona Therapeutics (ABEO) shares in June 2026?

The filing states the sale was made to cover tax obligations from the vesting of restricted stock awards. Such sales are typically mechanical, occurring when equity compensation vests and the insider needs cash to satisfy related income tax liabilities.

How many Abeona Therapeutics (ABEO) shares did Brendan O’Malley sell and at what prices?

He sold 4,826 shares at a weighted average price of $5.4295 on June 8, 2026, and 6,305 shares at a weighted average price of $5.3042 on June 9, 2026. In total, 11,131 common shares were sold in these transactions.

How many Abeona Therapeutics (ABEO) shares does Brendan O’Malley hold after the reported sales?

Following the June 2026 transactions, Brendan O’Malley directly owned 440,003 shares of Abeona Therapeutics common stock. This post-transaction figure reflects his remaining direct holdings after selling 11,131 shares to address tax obligations on vested awards.

Were Brendan O’Malley’s Abeona Therapeutics (ABEO) share sales part of routine compensation events?

Yes. A footnote explains the sales were executed to cover tax obligations from the vesting of restricted stock awards. This indicates the transactions are linked to routine equity compensation events, rather than discretionary portfolio changes or a change in long-term ownership stance.

How were the Abeona Therapeutics (ABEO) sale prices for Brendan O’Malley’s Form 4 calculated?

The filing reports weighted average sale prices. For June 8, 2026, shares were sold between $5.345 and $5.54, averaging $5.4295. For June 9, 2026, sales ranged from $5.24 to $5.47, averaging $5.3042, with detailed breakdowns available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Malley Brendan M.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		S(1)		4,826	D	$5.4295(2)	446,308	D
Common Stock	06/09/2026		S(1)		6,305	D	$5.3042(3)	440,003	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Brendan O'Malley	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)